Followers | 196 |
Posts | 11504 |
Boards Moderated | 0 |
Alias Born | 11/29/2007 |
Wednesday, March 25, 2020 8:06:19 AM
OT-101 and two additional candidates demonstrated viral inhibition activity against coronavirus
March 25, 2020 08:00 ET | Source: Mateon Therapeutics
AGOURA HILLS, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an update on its rapid antiviral response program targeting coronaviruses, initially targeting COVID-19. OT-101 continued to show significant activity against coronaviruses and in the new testing results, two additional therapeutic oligonucleotides designed to target COVID-19 also demonstrated potent anti-viral activity. The candidates were all designed to work synergistically to avoid resistant mutations frequently seen with viral infections. OT-101 and the other candidates work by inhibiting virus binding to its target, thereby stopping the virus from replicating itself and stopping viral induced pneumonia, which often leads to patient complications. The results of the new studies came through joint efforts between Mateon and its partner, Golden Mountain Partners, LLC (GMP), which have teamed up to build an international world class program for rapid response against COVID-19 and future epidemics.
The Company has begun preparations to submit an Investigational New Drug Application (IND) to the Food and Drug Administration (FDA) for OT-101 against COVID-19 to expedite testing in COVID-19 patients.
The collaborative effort was able to manufacture and test multiple new therapeutic drug candidates within weeks from time of viral sequencing. The effort was built on the companies experience with the specific antisense backbone and its well described safety profile. OT-101 is ready to move into clinical testing in COVID-19 patients and the new candidates can be ready shortly thereafter. The anti-sense program that Mateon has developed has the potential to go from concept to clinic in months, rather than years, which is highly suitable as a rapid response to pandemics.
Dr. Vuong Trieu, President and Chief Executive Officer of Mateon stated: “We are excited about our platform for rapid response against viral epidemics and look forward to working with GMP to further expand on that platform in the US and China.”
"When the facts change, I change my mind. What do you do, sir?"
Recent OTLC News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/27/2024 12:00:06 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 04:00:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 10:00:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 01:00:10 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM